Market Risers: Fresnillo, GlaxoSmithKline, Hargreaves Lansdown, Ilika

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

The share price for Fresnillo with company EPIC: LON:FRES has stepped up 4.14% or 52.5 points throughout the session so far. Buyers are a positive bunch during this period. The periods high has reached 1330.5 while the low for the session was 1278. The total volume of shares exchanged so far has reached 270,259 whilst the average number of shares exchanged is 1,725,356. The 52 week high for the share price is 1359.5 some 91.5 points in difference to the previous days close of business and a 52 week low sitting at 456.51 a difference of some 811.49 points. Fresnillo now has a 20 simple moving average of 1280.91 and a 50 day simple moving average now at 1170.36. The market cap now stands at £9,730.68m at the time of this report. Share price is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Fresnillo being recorded at Monday, September 7, 2020 at 12:30:43 PM GMT with the stock price trading at 1320.5 GBX.

The stock price for GlaxoSmithKline with company EPIC: LON:GSK has moved up 3.19% or 45.8 points during the course of today’s session so far. Traders have remained optimistic during this period. The periods high has reached 1481.2 while the low for the session was 1446. The total volume of shares traded by this point was 1,072,886 with the daily average number around 6,753,759. The 52 week high for the shares is 1857 equating to 421.8 points difference from the previous days close and putting the 52 week low at 1328.19 which is a variance of 107.01 points. GlaxoSmithKline now has a 20 SMA of 1543.72 and now the 50 day moving average now at 1591.35. Market capitalisation for the company is £74,307.16m at the time of this report. The currency for this stock is GBX. Market cap is measured in GBP. This article was written with the last trade for GlaxoSmithKline being recorded at Monday, September 7, 2020 at 12:32:21 PM GMT with the stock price trading at 1481 GBX.

Shares in Hargreaves Lansdown with EPIC code: LON:HL has stepped up 3.43% or 52.75 points throughout today’s trading session so far. Market buyers are a positive bunch during the session. The periods high figure was 1593.5 dropping as low as 1539. Volume total for shares traded during this period was 179,149 while the average shares exchanged is 832,849. The 52 week high for the shares is 2186 about 646.5 points difference from the previous close and the 52 week low at 1147 which is a difference of 392.5 points. Hargreaves Lansdown now has a 20 SMA at 1723.84 and the 50 day moving average at 1710.08. The current market capitalisation is £7,552.34m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for Hargreaves Lansdown being recorded at Monday, September 7, 2020 at 12:32:09 PM GMT with the stock price trading at 1592.25 GBX.

Shares of Ilika found using EPIC: LON:IKA has risen 5.31% or 4.25 points throughout the session so far. Investors have so far held a positive outlook throughout the trading session. The period high has peaked at 87 and a low of 83.1. The number of shares traded by this point in time totalled 29,246 with the daily average at 315,827. The 52 week high is 104 which comes in at 24 points difference from the previous days close and putting the 52 week low at 19.01 making a difference of 60.99 points. Ilika now has a 20 SMA at 77.34 and also a 50 day MA at 73.51. The current market cap is £116.77m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Ilika being recorded at Monday, September 7, 2020 at 12:24:12 PM GMT with the stock price trading at 84.25 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement.
Ilika plc appoints Cavendish Capital Markets as Nominated Adviser and Sole Broker, enhancing its solid-state battery technology ventures.
GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development.
GSK announces FDA review of Nucala for COPD treatment following successful MATINEE study data, aiming to be the first approved monthly biologic.

Search

Search